|

Struggles of Diagnosing Sarcomatoid Mesothelioma

ByHolly Zink
Struggles of Diagnosing Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma and sarcomatoid carcinoma can be hard to tell apart during diagnosis. A study published in Diagnostics reveals that a new panel test could help to distinguish between these two diseases.

Mesothelioma is caused by asbestos. There are three different types of mesothelioma: epithelioid, sarcomatoid, and biphasic.

Patients who are diagnosed with sarcomatoid mesothelioma face a much poorer outlook than those with the more common epithelioid form of the disease.

Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma is also the least common form of this already rare cancer. Sarcomatoid mesothelioma includes only about 10 percent of the 2,000 to 3,000 mesothelioma cases diagnosed in the United States each year.

Out of the three different types of mesothelioma, the sarcomatoid type is the most aggressive. Studies find that patients with sarcomatoid mesothelioma survive for an average of five to six months.

This is why an early diagnosis of mesothelioma is so important. If doctors could find a way to diagnose mesothelioma earlier, it could improve the odds of surviving it.

One way to diagnose mesothelioma is by testing the cells in a tissue sample, or biopsy. The biopsy is considered the most reliable diagnostic tool.

New Panel Test

Researchers in Italy tested the accuracy of a “two-hit” panel test to diagnose either sarcomatoid mesothelioma or sarcomatoid carcinoma.

The panel test measures Claudin-4 and BAP1. Claudin-4 is a biomarker produced by sarcomatoid carcinoma. BAP1 is a biomarker that is limited by sarcomatoid mesothelioma.

This panel was already successful in differentiating between epithelioid mesothelioma and conventional carcinoma. It had a 96% rate of diagnostic accuracy with these two cancers.

To test the panel against sarcomatoid mesothelioma and sarcomatoid carcinoma, the researchers looked at biopsy samples from past patients.

The researchers found that this this “two-hit” panel test was effective at differentiating between these two cancers. An additional biomarker panel may be needed for confirmation.

Source

Zuccatosta L, Bizzarro T, Rossi G, Gallo G, Gasparini S, Ambrosini-Spaltro A. Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. Diagnostics (Basel). 2023;13(2):249. Published 2023 Jan 9. doi:10.3390/diagnostics13020249. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858564/

Similar Posts

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma
| |

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

ByAlex Strauss

Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

Inflammation Both “Friend and Foe” in Mesothelioma
| |

Inflammation Both “Friend and Foe” in Mesothelioma

ByAlex Strauss

An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment
| |

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

ByAlex Strauss

In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

Mesothelioma Surgeons Report New Biopsy Technique
| |

Mesothelioma Surgeons Report New Biopsy Technique

ByAlex Strauss

A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

New Serum Marker Could Improve Mesothelioma Diagnosis
|

New Serum Marker Could Improve Mesothelioma Diagnosis

ByAlex Strauss

Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…